Products

Supply High Quality API CAS 202409 -33-4 Etoricoxib

China Supply High Quality API CAS 202409-33-4 Etoricoxib, Find details about China Etoricoxib, 202409-33-4 from Supply High Quality API CAS 202409-33-4 Etoricoxib

Model NO.
TY-02ALI
CAS No.
202409-33-4
Appearance
White Powder
Einecs
616-396-9
Assay
99%
Shelf
2 Years
Trademark
tongyon
Transport Package
25kg/Drum 1kg, 10kg, 100kg, 200kg
Specification
25kg/drum
Origin
China
Model NO.
TY-02ALI
CAS No.
202409-33-4
Appearance
White Powder
Einecs
616-396-9
Assay
99%
Shelf
2 Years
Trademark
tongyon
Transport Package
25kg/Drum 1kg, 10kg, 100kg, 200kg
Specification
25kg/drum
Origin
China
Supply High Quality API CAS 202409-33-4 Etoricoxib
Supply High Quality API CAS 202409-33-4 Etoricoxib

Supply High Quality API CAS 202409-33-4 Etoricoxib
 
Product nameEtoricoxib
CAS202409-33-4
Appearancewhite powder
Assay99%
StorageCool and Protect from light


Supply High Quality API CAS 202409-33-4 Etoricoxib

Product Name:Etoricoxib
CAS:202409-33-4
MF:C18H15ClN2O2S
MW:358.84
EINECS:682-421-5
Mol File:202409-33-4.mol
Melting point:134-135°C
Boiling point:510.0±50.0 °C(Predicted)
Density 1.298±0.06 g/cm3(Predicted)
storage temp. -20°C Freezer
pka4.5(at 25ºC)
form neat


Supply High Quality API CAS 202409-33-4 Etoricoxib


Etoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company with the chemical name being 5-chloro-6'-methyl-3-4-(methanesulfonamide) phenyl]-2, 3'-bipyridine. Etoricoxib has a unique chemical structure that is methylsulfonyl group. The introduction of this group can not only increase the selectivity for COX-2 drugs, but also does not produce sulfa drugs and cross-allergic reactions. Etoricoxib was first approved for entering into market in 2002 in the UK, followed by the marketing countries and regions including the European Union, Asia, Australia and Latin America. Until the end of 2013, it has been approved for marketing in 97 countries for being widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases. Etoricoxib has also entered into market in Taiwan and Hong Kong of China. It had entered into market in Chinese mainland in 2008 with the approved indications being acute gouty arthritis and OA and another indication being primary dysmenorrhea in the second half year of 2014.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.

Supply High Quality API CAS 202409-33-4 EtoricoxibSupply High Quality API CAS 202409-33-4 EtoricoxibSupply High Quality API CAS 202409-33-4 EtoricoxibSupply High Quality API CAS 202409-33-4 EtoricoxibSupply High Quality API CAS 202409-33-4 EtoricoxibSupply High Quality API CAS 202409-33-4 Etoricoxib

You Might Also Like